| Old Articles: <Older 4231-4240 Newer> |
|---|
 |
The Motley Fool
October 16, 2007
Brian Lawler |
Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note.   |
The Motley Fool
October 16, 2007
Brian Orelli |
Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note. |
The Motley Fool
October 16, 2007
Brian Lawler |
Genentech Fitting Better Cancer treatment Avastin continues to surge for the biopharma with a jump on the competition. Investors, take note. |
The Motley Fool
October 16, 2007
Billy Fisher |
A Heartbreaker at Medtronic The medical device maker halts distribution of certain defibrillator wires. Shares of Medtronic are now very close to the stock's 52-week low. |
The Motley Fool
October 15, 2007
Brian Lawler |
PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note. |
The Motley Fool
October 15, 2007
Brian Lawler |
A Surprising Decision for Telik It still doesn't look like the pharma's lead drug is helping anyone get better. Investors, take note. |
The Motley Fool
October 15, 2007
Brian Lawler |
Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note. |
BusinessWeek
October 22, 2007
Catherine Arnst |
Roll Up Your Sleeve, Gramps A graying population may create a huge market for vaccines that buttress aging immune systems. |
The Motley Fool
October 12, 2007
Billy Fisher |
Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward. |
The Motley Fool
October 12, 2007
Ryan Fuhrmann |
Dueling Fools: Johnson & Johnson Bull Rebuttal The bulls say that J&J's stock record speaks for itself, and that the current negative short-term news and flagging stock price have created a compelling risk/reward trade-off for investors. |
| <Older 4231-4240 Newer> Return to current articles. |
